BioDrugs

, Volume 17, Issue 6, pp 425–431

Tumour Necrosis Factor in Sarcoidosis and its Potential for Targeted Therapy

Authors

    • Interstitial Lung Disease and Sarcoidosis ClinicUniversity of Cincinnati Medical Center
  • Michael Iannuzzi
    • Henry Ford HospitalCase Western Reserve University
Therapy Review

DOI: 10.2165/00063030-200317060-00005

Cite this article as:
Baughman, R.P. & Iannuzzi, M. BioDrugs (2003) 17: 425. doi:10.2165/00063030-200317060-00005

Abstract

Tumour necrosis factor (TNF)-α is a potent cytokine involved in the inflammatory reactions of many acute and chronic diseases. Recently, agents that block TNFα either directly or indirectly have been successful in the treatment of a variety of immune-mediated inflammatory disorders including rheumatoid arthritis and Crohn’s disease. Sarcoidosis is an immune-mediated inflammatory disorder characterised by the formation of granulomas. TNFα is important in the initiation and perpetuation of inflammation in sarcoidosis, contributing to the initiation of granulomas and the progression of fibrosis, as well as to nongranulomatous inflammation. Various agents used to treat sarcoidosis affect TNF, including the most widely used drug class, corticosteroids, which are usually effective in blocking TNFα release from cells. Other agents that nonspecifically inhibit TNFα release include methotrexate, azathioprine and pentoxifylline. Specific TNF-antagonising biological agents such as infliximab and etanercept are being tested in patients with sarcoidosis, with mixed success. Infliximab has been shown to produce clinical improvement and reduce the requirement for corticosteroids in a small number of patients with sarcoidosis. However, as infliximab can be associated with reactivation of tuberculosis, which could be mistaken as worsening sarcoidosis, it should be used with caution in this patient group.

Copyright information

© Adis Data Information BV 2003